PXS-S1A/C [67,153] and PXS-5382A, which inhibit LOXL2, have also been shown to delay tumour growth and reduce collagen accumulation in orthotopic models of breast cancer [153], and in orthotopic LY2 oral cancer models [67], respectively. Here, LOXL2 is linked to breast carcinoma.